Cryptic commands
The Dutch study was led by Hans Clevers, director of the Hubrecht Institute, and examined the role of a poorly understood protein called leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; GPR49) in a mouse model of colon cancer.
In 2007, Clevers' team reported that Lgr5 was expressed in mouse crypt stem cells, but not in cells further up the sides of the crypt, and that cells lost the ability to divide indefinitely when they stopped expressing Lgr5. 3 Because colon cancer cells also divide indefinitely, the team hypothesized that Lgr5 could be a marker of the most proliferative cells in colorectal tumors.
To test this idea, the team disrupted the adenomatous polyposis coli (Apc) gene in cells with or without Lgr5. Apc is a tumor suppressor that puts the brakes on cell division in the colon and is absent in many colorectal cancers.
The team found that removal of Apc in Lgr5-positive cells indeed led to tumor formation, whereas knocking out Apc in neighboring cells had no effect.
"When we delete Apc in stem cells, we get explosive tumors, but if we delete it in other cells, the mice are fine, " Clevers told SciBX.
Moreover, cells that had already migrated out of the base of the crypt, and thus had stopped making Lgr5, did not develop into tumors 
Marker or target?
Both studies go a long way toward proving the cancer stem cell hypothesis, which predicts that a small subset of cells within a tumor is the real culprit behind the cancer. Most cancer therapeutics kill tumor cells with incomplete efficiency and may thus let a small minority of hidden cancer stem cells survive; identifying the true origin of a tumor is a major goal for drug development.
The problem is that targeting cells that bear LGR5 and CD133 is a challenge, since healthy versions of these cells are likely to be essential for the normal workings of the intestinal crypt.
As a result, Gilbertson believes that neither protein is likely to be a good direct drug target. "Both CD133 and LGR5 are expressed both in tumors and in the normal stem cells, so if you target them the result could be horrible, " he said.
Indeed, targeting all CD133-or LGR5-positive cells could kill healthy stem cells and prevent the intestinal lining from undergoing its daily process of self-renewal.
Nevertheless, said Gilbertson, "you can now look for drugs that selectively hit the malignant population" of tumor cells expressing CD133 and LGR5.
However, Clevers thinks that LGR5 is a "potentially excellent colon cancer target, " noting that although only about 2% of the cells in actively growing tumors are LGR5 positive, eradicating this subpopulation of cells would kill off the source of the remaining cancer cells. Clevers and the Royal Netherlands Academy of Arts and Sciences have sought patents on the use of LGR5 and a related protein, LGR6, as cancer stem cell markers and potential targets in regenerative medicine. The patents are being licensed to Agamyxis, a cancer company cofounded by Clevers, who is also the company's CSO.
"When we delete
Clevers and Agamyxis CEO Ton Logtenberg cofounded vaccine company Crucell N.V.
Agamyxis is focused on small molecule inhibitors of NOTCH1, an enzyme of the γ-secretase family that is a target in Barrett's disease, intestinal adenoma and adenocarcinoma. The company did not disclose whether the findings in Clevers' study relate to its NOTCH program.
According to Clevers, Agamyxis' lead compound is in preclinical development.
Gilbertson has not patented his team's findings. 
